In this context, the ALK kinase inhibitor crizotinib has been approved for the treatment of ALK-rearranged malignancies, and is now considered the standard of care for both early- and advanced-stage NSCLC patients [11,12]. Here, ALK is linked to non-small cell lung carcinoma.